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The medicinal mushroom Cordyceps sinensis collected from Himalayan region of India was found to have bioactive 
compounds. The mycelia free culture filtrate obtained from fermentation of Cordyceps mycelia were partially purified by 
solvent-solvent extractions. The subsequent fractions were tested for their potential regarding antibacterial and fibrinolytic 
activity. The butanolic fraction and aqueous layer showed significant antibacterial activity against six bacterial strains.While 
the final aqueous layer and hexane fraction showed partial fibrin lytic capacity in comparison with commercially available 
streptokinase as a positive control. It was assumed that the metabolite fractions when purified further can act as good 
antibacterial and fibrinolytic agents. 
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Introduction 
Fungi are found to be one of the best sources of 
alternative medicines apart from plants and bacteria. 
They have the potential to produce novel compounds 
which are medicinally very important
1
. Higher fungi 
especially medicinal mushrooms are being studied 
since ages for their bio-metabolites and are renowned 
for the treatment of various diseases
2
. One of the most 
important and demanding medicinal mushroom 
belongs to class ascomycetes is Cordyceps a soft  
gold, having a valuable source of natural products 
with diverse biological activities. This is 
entomopathogenic in nature and exists asgrowth from 
the body of infected insect
3
. Fungus C. sinensis is 
endemic to the grasslands and shrubs of Central Asia 
and grows in a frigid and arid environment at the 
elevations of 3500–4500 m
4,5
.  
This medicinal mushroom is considered as 
therapeutic bio-factory, which possesses anti-cancer, 
anti-metastatic, anti-microbial, anti-inflammatory, 
anti-oxidant and immuno-stimulating properties
6-7
. 
The cultivation and collection of Cordyceps from its 
habitat is challenging; because it is rare and scarce. 
However, the ever increasing demand of this 
medicinal mushroom and its metabolites leaves us 
with little choice but to cultivate it artificially
8-9
. 
Today C. sinensis becomes very prominent mushroom 
and cultivated from anamorphic mycelia for its 
medicinal and pharmaceutical properties
10
. 
The resistance in pathogenic organisms against 
various available drugs leads to necessitate the new 
drugs from new sources
11
. The disorders in fibrin 
network and blood clotting result in thrombosis, 
which induces deadly diseases like myocardial, 
cerebral and pulmonary infarction. Hence, the present 
study is based on the artificial cultivation of 
anamorphic mycelia of C. sinensis collected from 
Indian Himalayas. The metabolites obtained were 
then subjected to test for their antibacterial and 
fibrinolytic potential. 
 
Materials and Methods 
 
Collection and Isolation of Culture 
The Cordyceps sinensis fruting body was collected 
from Pithoragarh District of eastern Uttaranchal, India 
in the month of June-July 2014. The specimen was 
stored in a sterilized plastic bag and brought to the 
laboratory (Fungal Biotechnology and Invertebrate 
Pathology Laboratory) where it was grown on 
selected and optimized PPDA (potato dextrose agar 
with peptone) media plates at 20 ± 2°C for 10 days. 
Initially, small pieces were cut and taken out from the 
specimen and were surface sterilized by sodium 
hypochlorite and 70% ethanol in order to grow 
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specimen sample on media plates.The sterilized 
sample pieces were then placed on PPDA media 
plates. Culture growing from the edges of the samples 
was then sub-cultured to the fresh PPDA plates. The 
pure cultures were maintained on PPDA slants at 4°C 
for further use.  
 
Cultivation of Fungus for Metabolite Production 
The anamorphic mycelium of C. sinensis from 
culture plate was transferred aseptically to 250 ml 
flask containing 100 ml media (15 g glucose, 5 g 
peptone, 3 g KH2PO4, 1 g K2HPO4, 0.5g MgSO4,  
0.5 g NaCl in 1000 ml distilled water) and incubated 
at 20±2°C for 15-20 days. The extracellular 
metabolite was filtered through Whatman filter  
(paper no.1) (Thermo Fischer) and obtained filtrate was 
known as mycelial free culture filtrate (MFCF). The 
solvent-solvent extraction was performed by dissolving 
equal amount of MFCF and solvent in a separating 
funnel and was shaken for a particular time. Upon 
shaking the organic layer was separated and aqueous 
layer was continued with another solvent. This results in 
getting the solvents fraction one after the other. 
 
Antibacterial Activity 
The antibacterial activity of extracts from C. sinensis 
was carried out by using agar well diffusion assay
12
. 
In order to examine the positive control, highly 
concentrated antibiotic discs (HiMedia Laboratories, 
India) were tested along with solvent extracts in a 
bacterial plate. Diluted culture of six pathogenic 
bacteria Vibrio cholerae, Salmonella typhimurium 
(MTCC#3904), Escherichia coli (MTCC#82), 
Klebsiella pneumonia (MTCC#109), Bacillus subtilis 
(MTCC#441) and Staphylococcus aureus 
(MTCC#96) were made separately in test tubes. 
Eighty µl of bacterial culture was spread on the 
surface of nutrient agar plates. Twenty µl of solvent 
extracted sample (all organic layers; hexane, 
chloroform, n-butanol and final aqueous layer 
fractions of C. sinensis) was loaded into the wells  
(6 mm diameter) made in media plates and incubated 
at 37°C for 24hrs. Zone of inhibition were measured 
(in mm) with the help of zone measuring scale 
(HiMedia Laboratories, India). Experiment was 
performed in triplicate against each organism, a 
positive control and negative control for each plate 
was also made separately. 
Antibacterial activity of all the solvent fractions 
from C. sinensis metabolite along with standard 
antibiotic was statistically analyzed. Here, Student  
t-test was performed by using Microsoft Office 
Excel’s two-sample assuming unequal variances data 
analysis tool.  
 
Fibrinolytic Activity 
The best way to test the activity of 
fibrinolytic/thrombolytic compounds is via in vitro 
clot lysis method
13
. Venous blood from healthy 
human volunteers (without any previous anti-
coagulant therapy) was brought safely from University’s 
Health Centre with due permission and help of medical 
practitioner. Icikinase (Abbott, India) a recombinant 
streptokinase enzyme (15,00,000 IU/vial) was used as 
positive control. The different concentrations (100%, 
75%, 50% and 25%) of Icikinase were added to blood 
clot as positive control. Stock solution of Icikinase was 
made by dissolving 5 ml phosphate buffer saline to an 
Icikinase vial. Following procedure was used for in vitro 
clot lysis method:  
Five hundred µl of venous blood was taken in all 
pre-weighed sterilized Eppendorf tubes and were 
incubated at 37°C for 45 min for clot formation. 
Serum was completely removed carefully without 
disturbing the clot. Weight of clot was taken by 
subtracting from the weight of empty tubes. Two 
hundred fifty µl of test samples (hexane, chloroform, 
n-butanol and final aqueous layer fractions of  
C. sinensis) and different concentrations of positive 
control were added to the clot and incubated at 37°C 
for 90 min for clot lysis. Water was used as negative 
control. Fluid obtained after incubation was removed 
and tubes were weighed again. Difference obtained in 
weight taken before and after clot disruption was 
expressed as percentage of clot lysis. 
 
Results and Discussion 
 
Isolation of Cordyceps 
The insect-borne fungus Cordyceps sinensis 
(Ophiocordyceps sinensis) is a well-recognized 
medicinal mushroom
14
. The traditional medicine 
system and modern ethno-medicine exploits majority 
of its bioactive compounds but the most used one is 
cordycepin (3’ deoxyadenosine)
10
. Apart from 
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 and hypolipidemic activity
22
. In present 
study, fruiting body of the specimen collected was found 




to divide into two part viz. stipe (the fruiting body,  
1.5–6 cm in length) and stroma (insect tissue infected 
with fungal mycelia, 3–5 cm in length). The colour of 
stroma was yellowish brown while stipe was dark brown 
to black in colour. Fruiting body with insect cadaver was 
4–12 cm in length while 3–4 mm in diameter. The 
fruiting body of Cordyceps sp. collected from 
Uttaranchal, India was grown vegetatively in solid and 
liquid media both (Fig. 1).  
 
Antibacterial Activity 
The antibacterial activity was performed by agar 
well diffusion assay against six test bacterial strains. 
Among these bacterial strains, two are Gram-positive 
(B. subtilis and S. aureus) and rest four are  
Gram-negative (V. cholerae, K. pnuemoniae, E. coli 
and S. typhi) in nature. All six bacterial strains were 
tested against the C. sinensis metabolites which were 
extracted by solvents. The n-butanol, hexane and 
chloroform fractions were tested along with crude 
metabolite and positive control. The graph in figure 
Fig 1 showed, butanolic extract with maximum zone 
of inhibition against all the tested bacterial strains. 
Their zone of inhibitions are 16mm, 12mm, 17mm, 
17mm, 14mm and 16mm for bacteria B. subtilis,  
E. coli, S. typhi, S. aureus, V. choleraeand K. 
pnuemoniae, respectively. Final aqueous layer also 
showed some amount of antibacterial potential against 
the three test bacterial strains. These three strains are 
B. subtilis, E. coli and S. aureus showing zone of 
inhibition 10mm, 12mm and 12mm respectively.  
For the confirmation of antibacterial activity by  
C. sinensis pure solvents were also tested which 
showed least or no activity against any of the test 
bacterial strains. The chloroform, hexane fraction and 
negative control (distilled water) didn’t show any 
zone of inhibition against any of the test bacterial 
strains. On the other hand positive control antibiotic 
did show high zone of inhibition against all the test 
bacterial strains. An average mean of a zone of 
inhibition from all the tested plates was taken which 
showed a high antibacterial activity (Figs. 2 & 3).  
The antibacterial activity of different solvent 
fractions of C. sinensis was analyzed statistically. It 
 
 




Fig. 2 — Zone of inhibition against growth of test bacterial strains by solvent extracts of C. sinensis 
Ae = aqueous layer, Be = n-butanol extract, Bp = n-butanol pure 
Antibiotic (a) was used as positive control and distilled water (w) was used as negative control 




was found that the butanolic and aqueous extract 
along with antibiotic standard was found significant at 
5% significance level. The t-value for aqueous and 
butanolic extract was found 3.61 and that of butanolic 
and standard antibiotic was found 5.39. Both the 
values were found more than t-critical value hence, 
the results were found statistically significant as 
shown in Table 1. 
Similarly, Dong et al
23
. used methanolic extract 
obtained from the fermentation of C. militaris  
mycelia was subjected to the test of antimicrobial 
(antibacterial and anti-fungal) potential by agar well 
diffusion method. The antibacterial activity of  
C. sinensis (CSEs) was also subjected to and 
determined by disc diffusion assay. Alcoholic extracts 
of various minimum inhibitory concentration (MIC) 
of CS25, CS50, CS75 and CS100 were  
tested against three bacterial strains. As a result the 
CS25, CS75 and CS100 of alcoholic extracts were 
found to be more effective against E. coli,  
P. aeruginosa and B. subtilis showing a zone of 
inhibition of 9 mm, 7 mm and 6.5 mm, respectively. 
Their concentrations were 93.75 µg, 93.75 µg and  
45 µg, respectively. The aqueous extract showed 





tested various extracts obtained from 
Cordyceps militaris 3936 strain via agar well 
diffusion method. Their results shows that butanolic 
extract have maximum antimicrobial activity against 
all tested bacterial and fungal strains. The reason for 
antimicrobial activity was might be the presence of 
cordycepin or its derivative in Cordyceps derived 
extracts. Also Holbein et al
26
. investigated the toxicity 
of cordycepin in yeast cells by inhibiting RNA 
synthesis. In the present research work on 
antibacterial assay, results showed that the butanolic 
extract of C. sinensis metabolite can act as a 
promising antibacterial agent against all the tested 
bacterial strains. Further, the final aqueous layer could 
be taken as an antibacterial agent against only three 
tested bacterial strains viz. B. subtilis, E. coli and  
S. aureus. Hence, C. sinensis extracts might have 
cordycepin or its derivative as an active ingredient 
showing antibacterial activity. These extracts when 
further purified can be used for the development of 
drugs in pharmaceutical industries. 
 
Fibrinolytic Activity 
A novel fibrinolytic enzyme was produced by 
submerged fermentation of C. militaris culture. As the 
enzyme could degrade thrombin therefore it could be 





Fig. 3 — Antibacerial activity of plates showing zone of 
inhibition of extracts from Cordyceps sinensis with respect to 
positive and negative control 
AL = aqueous layer, n-B = n-butanol, 1 = extract, 4 = crude,  
3 = pure solvent, 5 = antibiotic (positive control), w = distilled 
water (negative control). Bs - B. subtilis, Ec - E. coli, St - S. typhi, 
Sa - S. aureus, Vc - V. cholerae, Kp - K. pnuemoniae. 
 
Table 1 — Student t-Test statistics for antibacterial activity  
of potent C. sinensis solvent fractions: 
  Ae Be 
Mean 5.666667 15.33333 
Variance 39.06667 3.866667 
Observations 6 6 
Hypothesized mean difference 0  
Df 6  
t Stat -3.61372  
P(T < = t) one-tail 0.00559  
t Critical one-tail 1.94318  
P(T < = t) two-tail 0.011181  
t Critical two-tail 2.446912  
   
  Be a 
Mean 15.33333 20.875 
Variance 3.866667 2.46875 
Observations 6 6 
Hypothesized mean difference 0  
Df 10  
t Stat -5.39298  
P(T < = t) one-tail 0.000152  
t Critical one-tail 1.812461  
P(T < = t) two-tail 0.000304  
t Critical two-tail 2.228139  
Be- Butanolic extract, Ae – aqueous extract, a – standard 
antibiotic 
 




Here in this research work, the in vitro clot lysis 
activity of C. sinensis solvent fractions (butanolic, 
hexane, chloroform fraction and final aqueous layer) 
was performed with reference to streptokinase. The  
C. sinensis fraction and crude metabolite along with 
positive control (streptokinase) and negative control 
(water) was added in blood clot separately and was 
allowed to react. Figure 4 shows a clear representation 
of clot lysis by different samples. In case of positive 
control streptokinase, concentrations like 100%, 75%, 
50% and 25% show significant clot lysis activity with 
percentage clot lysis of 78.26, 49.50, 45.83 and 37.82 
respectively. This shows that with decrease in the 
percentage of streptokinase, clot lysis activity also 
decreases. On the other hand, the negative control 
water shows 1.03% of lysis which was considered 
negligible. In case of the test samples, the solvent 
fractions of C. sinensis metabolite also showed clot 
lysis activity. Crude metabolite showed 9.18% of clot 
lysis and hexane fraction showed 19.78% of clot lysis, 
while the final aqueous layer obtained in solvent-
solvent extraction of C. sinensis metabolite showed 
48.33% of clot lysis. In comparison with streptokinase 
tested concentrations, 48.33% lysis lie between 75% 
and 50% of concentration (Table 2). Rest of the 
fractions showed no dissolution of blood. The formula 
for clot lysis percentage was calculated as under: 
Clot weight = weight of tube containing clot – weight 
of empty tube 
Clot lysis (%) = 
weight  of  lysis
weight  of  clot  before  lysis
× 100 
Similarly, in vitro anti-coagulant capacity of 
enzyme purified in saline from C. militaris was also 
studied in coagulated blood. Sample was tested  
along with heparin and control saline separately. 
Apparently, no coagulation was observed either in 
heparin or in samples (purified enzyme) tube after  
3 hrs but after 24 hrs blood was found to be partially 
coagulated in heparin tube and sample tube showed 
complete dissolution of the blood clot. It was because 
of an enzyme from C. militaryis which significantly 
acts as an anti-coagulant and is quite better than  
that of heparin. The enzyme isolated by Liu et al. 
 
 
Fig. 4 — Fibrinolytic activity of C. sinensis extract with respect to control 
A – water, B – MFCF, C – hexane extract, D – aqueous extract, E – 25% streptokinase, F – 50% streptokinase, G – 75% streptokinase,  
H – 100% streptokinase 
 
Table 2 — Effect of C. sinensis extracts on in vitro clot lysis along with positive and negative control 
S. No. Type of sample Weight of clot Weight of lysis Clot lysis % 
1 S 100% 0.184 0.144 78.26 
2 S 75% 0.204 0.101 49.50 
3 S 50% 0.168 0.077 45.83 
4 S 25% 0.193 0.073 37.82 
5 Water 0.193 0.002 1.03 
6 Crude 0.185 0.017 9.18 
7 Caqueous layer 0.180 0.087 48.33 
8 Cbutanol 0.176 −0.084 – 
9 Chexane 0.187 0.037 19.78 
10 Cchloroform 0.189 −0.061 – 
11 Butanol 0.171 −0.075 – 
S = streptokinase, C = extract of C. sinensis 




from C. militaris is a novel fibrinolytic enzyme whose 
molecular weight is 28 kDa. It can act as plasmin like 
protein as well as plasminogen activator which 
remains active at pH 7.2 and temperature 37°C. Here 
in the current study, the partial lysis of metabolite 
fractions on purification could give complete lysis of 
clot. From the above observations it can be assured 
that the fraction of C. sinensis metabolite may act as a 
good fibrin lytic drug after complete purification.  
 
Conclusion 
In the present research, the fruiting body of 
Cordyceps sinensis was collected from the Himalayan 
region, Uttarakhand, India. The metabolite obtained 
from anamorphic mycelia was subjected to the solvent 
fractions which showed characteristic anti-bacterial 
and fibrinolytic activities. The butanolic fraction was 
found to have a potential antibacterial activity against 
all the tested pathogenic bacterial strains, while that of 
the aqueous extract showed partial anti-coagulant 
property. After complete purification of both the 
extracts, obtained subsequent products could be 
estimated to be used as an antibiotic drug and 
fibrinolytic drug by pharmaceutical industries. The 
intravascular thrombosis is the main cause of 
cardiovascular diseases which may be treated by 
using these natural thrombolytic extracts after 
complete purification. Based on the facts, extracts 
from ―Himalayan soft gold mushroom Cordyceps 
sinensis‖ can help in prevention of microbial 
infections as well as obstructions created by clots in 
blood streams.  
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